Self-administered COgnitive Personalized Training in Early Psychosis

NCT ID: NCT06634446

Last Updated: 2024-10-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-10-26

Study Completion Date

2027-12-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overall objective of SCOPe is to improve early intervention in psychosis by providing an innovative eHealth tool that will enable personalized cognitive training, adapted to the individual's cognitive abilities.

Cognitive remediation improves quality of life and functional outcome in patients with chronic psychosis. It would even be more efficacious in the early phase of psychosis by tackling the negative impact of psychosis on education achievement and employment. However, cognitive dysfunctions are often overlooked in FEP and cognitive remediation is not always accessible. New technologies can provide us with youth-friendly, non-stigmatizing tools, such as self administered, training applications so that all first-line clinical settings or professionals, and in fine all patients, can have access, wherever they live, to personalized cognitive training focusing on impaired functions.

Early psychosis can be associated with inflammation, metabolic deficiency, as well as early structural brain anomalies that reflect brain plasticity abilities and could influence the prognosis and response to cognitive training.

Our background hypothesis is that promoting neuroplasticity by cognitive training could attenuate or reverse early cognitive deficits and improve the overall functional outcome in young patients experiencing FEP and that this effect is modulated by individual brain plasticity abilities.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

First Episode Psychosis (FEP)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental group

the experimental group will use a mobile application for cognitive training for 3 months.

Group Type EXPERIMENTAL

a mobile application for cognitive training

Intervention Type DEVICE

Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.

HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.

Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.

User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians.

comparative control group

Patients in the control group will use video games with no prominent cognitive involvement

Group Type ACTIVE_COMPARATOR

video games

Intervention Type DEVICE

Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

a mobile application for cognitive training

Personalized cognitive training (PCT) HappyNeuronwill be delivered via a tablet or mobile application for 24 hours within 12 weeks, with a weekly supervision-call to reinforce their motivation.

HappyNeuron Pro is a digital therapy tool designed for clinicians to provide engaging cognitive therapy via a web-based platform. It is compatible with PC, Mac, iPad, and Android devices and is available in multiple languages. The tool features exercises from established cognitive remediation programs.

Functionality: The program offers 22 cognitive exercises targeting seven key functions outlined in the MATRICS framework: Processing Speed, Selective Attention, Reasoning and Working Memory, Verbal Memory, Visual Memory, and Auditory Memory. Exercises are customizable to meet individual patient needs, facilitating personalized cognitive training.

User Experience: Each session comprises brief, self-administered exercises, with the order and difficulty adjusted by clinicians.

Intervention Type DEVICE

video games

Patients in the control group will use video games with no prominent cognitive involvement no prominent cognitive involvement

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

cognitive training HappyNeuron Pro Personalized cognitive training

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adolescent and young adults, both genders, aged 16 to 35,
* Seeking help in one of the recruiting centers,
* Newly diagnosed as experiencing an Episode of Psychosis (reaching criteria as described in the Comprehensive Assessment of at Risk Mental States (CAARMS) within the year
* Written informed consent signed (and from one legal guardian for minors).

Exclusion Criteria

* Severe and unstabilized medical conditions,
* Insufficient level in reading and/or French language,
* Absence of medical insurance,
* Participation in another intervention trial,
* Enforced hospitalization (ASPDT, ASPPI, ASPRE),
* Intellectuel Deficiency (IQ\<70), and / or sensorimotor deficits incompatible with the cognitive training,
Minimum Eligible Age

16 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre Hospitalier St Anne

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marie Odile MO KREBS, PROFESSEUR

Role: PRINCIPAL_INVESTIGATOR

GHU PARIS Saint-Anne

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Groupe Hospitalier Universitaire Paris - Psychiatrie et Neurosciences, (GHU Paris)

Paris, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie Odile KREBS, PROFESSEUR

Role: CONTACT

+331 456 586 46

Linda SCORIELS, PhD

Role: CONTACT

+33140789269

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Khaoussou SYLLA, PhD

Role: primary

0031 45 65 81 66

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2019 A00399 48

Identifier Type: REGISTRY

Identifier Source: secondary_id

D19-P002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

mHealth for Psychosis Help-seeking
NCT05905601 COMPLETED NA
EPI-MINN: Targeting Cognition and Motivation
NCT05112432 ACTIVE_NOT_RECRUITING NA